Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MN-166 (ibudilast) Biomarker Study in ALS
NCT02714036Phase 2Completed
- Sponsor
- MediciNova, Inc.
- Start
- May 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibudilast in amyotrophic lateral sclerosis (ALS), sponsored by MediciNova, Inc.. Started May 2016; status: completed.
02
Drugs
ibudilast
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02714036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02714036.